HCAT

Health Catalyst, Inc. Common Stock (HCAT) | Rumor.io

Health Catalyst

HCAT

Attention (50-day avg)0%

Attention rank (50-day avg)#3,526

Bullish sentiment (50-day avg)33%

Price to earnings ratio-0.69

Market capitalization133.2M

Earnings per share-3.68

Dividend yield (TTM)—

Revenue (annual)311.1M

Net income (annual)-178M

Social

What share of all stock conversation is about HCAT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 5

Health Catalyst has agreed to sell its Vitalware business to Med-Metrix for $147 million, with the transaction expected to close in Q3 2026.
The sale is expected to strengthen Health Catalyst's balance sheet and sharpen its strategic focus, with the company's shares surging 9.28% on the day.
The transaction is seen as a positive development for Health Catalyst, with the company's stock price looking strong on a 4-hour chart, with key support levels at $1.40-$1.50 and a next key level to test at $2.35-$2.55.

Generated by AI

Sentiment

Of the messages about HCAT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% new	65.28% -9.72
Bearish	—	—	0% -100	34.72% +9.72

Bullish· Aug 24

$HCAT is poised for significant growth, with a strong team in place and a loyal community.
The company's low market capitalization and high level of community engagement make it an attractive investment opportunity.
$HCAT has the potential to reach new all-time highs, driven by a combination of strong fundamentals and a dedicated following.

Bearish· Aug 5

$HCAT's business model is considered ridiculous, with high G&A expenses and stock comp, and the company issued horrible guidance while still being FCF negative.
$HCAT's guidance was weaker than expected, leading to a 25% premarket stock price drop, and the company's stock buyback is likely to be ineffective due to high stock comp issuance.
Analysts have downgraded $HCAT to hold or neutral, with price targets lowered to $16 from $20, $27, or higher, indicating a lack of confidence in the company's future performance.

Generated by AI

Topics

Of the messages about HCAT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	44.94%
Technical Analysis	—	0%	0%	39.33%
Earnings	—	0%	0%	6.74%
Analysts	—	0%	0%	8.99%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Earnings· Nov 12

Health Catalyst (HCAT) beats earnings estimates by $0.10 and revenue expectations.
HCAT reports a loss of $0.54, which is narrower than the consensus estimate of a loss of $0.64.
HCAT's Q3 non-GAAP EPS of -$0.27 beats estimates, while GAAP EPS of -$1.40 misses by $0.98, and revenue of $39.42M beats by $1.65M.

Analysts· May 7

Raymond James analyst John Ransom maintains Health Catalyst with a Strong Buy and raises the price target from $56 to $63.
SVB Leerink maintains Health Catalyst with an Outperform and raises the price target from $53 to $59.
Goldman Sachs maintains Health Catalyst with a Buy and raises the price target from $54 to $60.

Generated by AI

Community

Of the messages about HCAT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	14.29%	16.84%
Newcomers	—	100%	85.71%	83.16%

Regulars· May 10

Health Catalyst's (HCAT) Q1 earnings were downgraded to "Neutral" by Guggenheim and to "Market Perform" by Raymond James, citing concerns about the company's growth prospects.
HCAT's Q1 earnings report showed a decline in revenue, with the stock down 13.30% and 10.18% in the last 5 and 19 minutes, respectively.
Guggenheim and Raymond James have both downgraded HCAT to a "Neutral" or "Market Perform" rating, citing concerns about the company's growth prospects and declining revenue.

Newcomers· Jun 4

Health Catalyst ($HCAT) is divesting its Vitalware revenue integrity business for $147 million in cash, a deal that will accelerate the company's strategic transformation.
The divestiture will enable Health Catalyst to repay its approximately $160 million term loan, eliminating the debt burden and allowing the company to focus on its AI and healthcare analytics core operations.
The deal has already led to a significant increase in the company's stock price, with $HCAT up 33% and 38% respectively, and a potential squeeze risk due to the high short interest.

Generated by AI

Health Catalyst is back in focus after analysts revised fair value from about US$2.10 to roughly US$1.83 per share, which points to a more cautious stance on the stock. Recent research has shifted from earlier optimism with price targets in the US$2 to US$3 range to current levels closer to US$1.80, as analysts weigh execution risks around churn, divestitures and the durability of growth in its health technology offerings. In this article, you will see how these changing targets fit into the...

11d agoYahoo Finance

Health Catalyst Reports Q2 2026 Results: Full Earnings Call Transcript

12d agoBenzinga

3 Small-Cap Stocks We Steer Clear Of

Detailed price information for Marketaxess Holdings (MKTX-Q) from The Globe and Mail including charting and trades.

12d agoThe Globe and Mail

Health Catalyst Adds Tami Reller to Board for Growth

Detailed price information for Health Catalyst Inc (HCAT-Q) from The Globe and Mail including charting and trades.

14d agoThe Globe and Mail

Health Catalyst appoints Tami Reller to board of directors

15d agoInvesting.com

3 Value Stocks That Concern Us

Detailed price information for Health Catalyst Inc (HCAT-Q) from The Globe and Mail including charting and trades.

19d agoThe Globe and Mail

Also Discussed

Investors talking about HCAT also mention

#	Name	Attention
1	Akso Health Group ADRAHG	0%0
2	ACCD - Accolade, Inc.	——
3	Progyny IncPGNY	0%0
4	GVP - GSE Systems, Inc.	——
5	HealthEquity, Inc.HQY	0%new
6	AxoGen IncAXGN	0%new
7	PagerDuty Inc.PD	0%new
8	Phreesia Inc.PHR	0%new
9	NEOS Enhanced Income 1-3 Month T-Bill ETFCSHI	0.04%new
10	Global Business Travel Group, Inc.GBTG	0%new

Health Catalyst, Inc. Common Stock

Healthcare
Health Information Services

Health Catalyst, Inc. is a healthcare data and analytics technology company that provides software and services to healthcare organizations. Health Catalyst, Inc. focuses on helping hospitals, health systems, and other providers unify clinical, financial, and operational data through its analytics platform and related applications. Its offerings support areas such as quality improvement, population health, revenue cycle performance, and cost management, enabling organizations to turn fragmented information into actionable insights. The company also delivers professional services that help clients implement, configure, and use its technology more effectively. Health Catalyst, Inc. plays a role in the health information services market by supplying tools that support data-driven decision-making across the healthcare industry.

Website

Location

10897 South River Front Parkway

South Jordan, UT, 84095

United States

Social

What share of all stock conversation is about HCAT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 5

Health Catalyst has agreed to sell its Vitalware business to Med-Metrix for $147 million, with the transaction expected to close in Q3 2026.
The sale is expected to strengthen Health Catalyst's balance sheet and sharpen its strategic focus, with the company's shares surging 9.28% on the day.
The transaction is seen as a positive development for Health Catalyst, with the company's stock price looking strong on a 4-hour chart, with key support levels at $1.40-$1.50 and a next key level to test at $2.35-$2.55.

Generated by AI

Sentiment

Of the messages about HCAT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% new	65.28% -9.72
Bearish	—	—	0% -100	34.72% +9.72

Bullish· Aug 24

$HCAT is poised for significant growth, with a strong team in place and a loyal community.
The company's low market capitalization and high level of community engagement make it an attractive investment opportunity.
$HCAT has the potential to reach new all-time highs, driven by a combination of strong fundamentals and a dedicated following.

Bearish· Aug 5

$HCAT's business model is considered ridiculous, with high G&A expenses and stock comp, and the company issued horrible guidance while still being FCF negative.
$HCAT's guidance was weaker than expected, leading to a 25% premarket stock price drop, and the company's stock buyback is likely to be ineffective due to high stock comp issuance.
Analysts have downgraded $HCAT to hold or neutral, with price targets lowered to $16 from $20, $27, or higher, indicating a lack of confidence in the company's future performance.

Generated by AI

Topics

Of the messages about HCAT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	44.94%
Technical Analysis	—	0%	0%	39.33%
Earnings	—	0%	0%	6.74%
Analysts	—	0%	0%	8.99%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Earnings· Nov 12

Health Catalyst (HCAT) beats earnings estimates by $0.10 and revenue expectations.
HCAT reports a loss of $0.54, which is narrower than the consensus estimate of a loss of $0.64.
HCAT's Q3 non-GAAP EPS of -$0.27 beats estimates, while GAAP EPS of -$1.40 misses by $0.98, and revenue of $39.42M beats by $1.65M.

Analysts· May 7

Raymond James analyst John Ransom maintains Health Catalyst with a Strong Buy and raises the price target from $56 to $63.
SVB Leerink maintains Health Catalyst with an Outperform and raises the price target from $53 to $59.
Goldman Sachs maintains Health Catalyst with a Buy and raises the price target from $54 to $60.

Generated by AI

Community

Of the messages about HCAT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	14.29%	16.84%
Newcomers	—	100%	85.71%	83.16%

Regulars· May 10

Health Catalyst's (HCAT) Q1 earnings were downgraded to "Neutral" by Guggenheim and to "Market Perform" by Raymond James, citing concerns about the company's growth prospects.
HCAT's Q1 earnings report showed a decline in revenue, with the stock down 13.30% and 10.18% in the last 5 and 19 minutes, respectively.
Guggenheim and Raymond James have both downgraded HCAT to a "Neutral" or "Market Perform" rating, citing concerns about the company's growth prospects and declining revenue.

Newcomers· Jun 4

Health Catalyst ($HCAT) is divesting its Vitalware revenue integrity business for $147 million in cash, a deal that will accelerate the company's strategic transformation.
The divestiture will enable Health Catalyst to repay its approximately $160 million term loan, eliminating the debt burden and allowing the company to focus on its AI and healthcare analytics core operations.
The deal has already led to a significant increase in the company's stock price, with $HCAT up 33% and 38% respectively, and a potential squeeze risk due to the high short interest.

Generated by AI

Health Catalyst

Social

Jun 5

Bullish· Aug 24

Bearish· Aug 5

Earnings· Nov 12

Analysts· May 7

Regulars· May 10

Newcomers· Jun 4

Health Catalyst (HCAT) Stock Fair Value Falls As Analysts Cut Targets On Growth Risks

Health Catalyst Reports Q2 2026 Results: Full Earnings Call Transcript

3 Small-Cap Stocks We Steer Clear Of

Health Catalyst Adds Tami Reller to Board for Growth

Health Catalyst appoints Tami Reller to board of directors

3 Value Stocks That Concern Us

Also Discussed

Health Catalyst, Inc. Common Stock

Company Information

Location

Health Catalyst (HCAT) Stock Fair Value Falls As Analysts Cut Targets On Growth Risks

Health Catalyst Reports Q2 2026 Results: Full Earnings Call Transcript

3 Small-Cap Stocks We Steer Clear Of

Health Catalyst Adds Tami Reller to Board for Growth

Health Catalyst appoints Tami Reller to board of directors

3 Value Stocks That Concern Us

Also Discussed

Social

Jun 5

Bullish· Aug 24

Bearish· Aug 5

Earnings· Nov 12

Analysts· May 7

Regulars· May 10

Newcomers· Jun 4